Advances for STADA-Xbrane’s Ximluci in Europe, the UK and the US

Biosimilars/News | Posted 04/05/2023 post-comment0 Post your comment

The STADA and Xbrane co-developed Ximluci, ranibizumab biosimilar is to launch in Europe and will now also be available on the UK’s National Health Service (NHS). In addition, the partners have submitted their Biologics License Application (BLA) to the US Food and Drug Administration (FDA).


The European Commission granted marketing authorization for Ximluci, a biosimilar referencing Lucentis ranibizumab, in 2022 [1, 2].  The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorization for Ximluci, in February 2023 [3]. Now, the ranibizumab biosimilar will be available as a 2.3 mg/0.23 mL single-use vial for injection for intravitreal use in these regions. The NHS supply contract runs from 1 April 2023 to 31 March 2024 and has a nominal total value of £70 million (€79 million), although this is dependent on factors such as the ability to capture share within the market segment.

Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor. It can be used to treat macular degeneration by inhibiting VEGF, which is responsible for the excessive formation of blood vessels in the retina leading to progressive loss of vision [4]. It is a monoclonal antibody drug and has been approved in the European Union and the UK, for the treatment of wet age-related macular degeneration (AMD), diabetic macular oedema (DME), diabetic retinopathy (PDR), retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularization (CNV) in adults.

‘Supplying ranibizumab to the NHS represents a further opportunity for STADA to improve patient access through competition on specialty medicines, and thereby deliver on our purpose of Caring for People’s Health as a Trusted Partner’, commented STADA’s Global Head of Specialty, Bryan Kim.

STADA and Xbrane submitted their BLA to FDA and expect a decision regarding this in early 2024.

Related articles
Canada approves ranibizumab biosimilar Byooviz

Phase III trial evidence used in approval of ranibizumab biosimilar Byooviz 

Fresh partnerships announced for ranibizumab and trastuzumab biosimilars

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Avanzar en el desarrollo de medicamentos biosimilares con biomarcadores farmacodinámicos

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Avanzar en el desarrollo de medicamentos biosimilares con biomarcadores farmacodinámicos

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Australia and EU: Alvotech Humira and Stada Lucentis biosimilars approved []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 May 4]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative.  Progress for Lucentis (ranibizumab) biosimilars in Europe and the US []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 May 4]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Ranibizumab biosimilar Ximluci and Amelivu to launch in the UK and South Korea []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 May 4]. Available from:
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ranibizumab (  []. Mol, Belgium: Pro Pharma Communications International; [cited 2023 May 4]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010